Study Uses Flu Virus to Speed Up COVID-19 Antibodies
A new vaccine may help speed up the process of making antibodies against SARS-CoV-2 by using preexisting immunity to a separate virus (the influenza virus).
Study Will Test Vaccine That Kills Cancer Cells Without Side Effects
A new cancer vaccine designed to detect and fight cancer cells without traditional cancer treatment is entering Phase III clinical trials.
Study Shows Patients Vaccinated Against Ebola Are Half as Likely to Die Than Unvaccinated Patients
A new study showed patients with confirmed Ebola virus disease were half as likely to die if they were vaccinated against the virus than if they were not.
Study Shows Positive Results for mRNA-Based Combination Influenza and COVID-19 Vaccine
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech’s mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
FDA Approves Vaccine for Meningococcal Disease in Adolescents
Pfizer’s PENBRAYA, a vaccine for meningococcal groups A, B, C, W and Y, has been approved by the U.S. Food and Drug Administration (FDA).
Just Arrived: A Trio of Active and Passive Vaccines Against RSV
For decades, respiratory syncytial virus (RSV) has defied the best efforts of vaccine makers to bring it to heel, until now.
Merck’s Ebola Vaccine Approved for the Pediatric Population
An expanded indication for ERVECO for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older has been approved by the U.S. Food and Drug Administration.
Study Finds Adult Vaccines Potentially Protect Against Alzheimer’s
A new study conducted at the University of Texas Health Science Center at Houston found that people who received shingles and pneumonia vaccines — along with tetanus and diphtheria — had as much as a 30 percent reduced risk of developing Alzheimer’s the most common type of dementia.
FDA Approves Pfizer’s ABRYSVO Vaccine for the Prevention of RSV
Pfizer’s ABRYSVO, a respiratory syncytial virus (RSV) vaccine, has been approved by the U.S. Food and Drug Administration for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to 6 months of age by active immunization of pregnant women at 32 through 36 weeks gestational age.
How Medical Misinformation About Vaccines is Spread
Politicization and polarization have made finding credible information online harder than ever.
